Thousands living with forms of arthritis that affect younger people will soon benefit from a new drug which has been approved by
NHS health chiefs.
Pivotal studies have found that the drug, bimekizumab, can dramatically reduce joint pain and swelling for those with a type of arthritis linked to the skin condition psoriasis, known as psoriatic arthritis.
Separate research has found it can also improve the debilitating symptoms of axial spondyloarthritis, known as axial SpA, another type of arthritis that causes pain and stiffness in the lower back when the joints become swollen.
Bimekizumab is particularly effective for those who are resistant to other treatments, offering a crucial solution to patients who have run out of options.
